ES2991523T3 - Suspensión de edaravona destinada a ser administrada por vía oral - Google Patents
Suspensión de edaravona destinada a ser administrada por vía oral Download PDFInfo
- Publication number
- ES2991523T3 ES2991523T3 ES19880770T ES19880770T ES2991523T3 ES 2991523 T3 ES2991523 T3 ES 2991523T3 ES 19880770 T ES19880770 T ES 19880770T ES 19880770 T ES19880770 T ES 19880770T ES 2991523 T3 ES2991523 T3 ES 2991523T3
- Authority
- ES
- Spain
- Prior art keywords
- edaravone
- suspension
- dispersant
- particles
- suspension according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018207646 | 2018-11-02 | ||
| PCT/JP2019/043013 WO2020091036A1 (ja) | 2018-11-02 | 2019-11-01 | 経口投与用エダラボン懸濁剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2991523T3 true ES2991523T3 (es) | 2024-12-03 |
Family
ID=70463399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19880770T Active ES2991523T3 (es) | 2018-11-02 | 2019-11-01 | Suspensión de edaravona destinada a ser administrada por vía oral |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10987341B2 (enExample) |
| EP (2) | EP3875085B1 (enExample) |
| JP (3) | JP7274502B2 (enExample) |
| KR (1) | KR20210087490A (enExample) |
| CN (4) | CN117398346A (enExample) |
| AR (1) | AR116967A1 (enExample) |
| AU (2) | AU2019369843A1 (enExample) |
| BR (1) | BR112021008197A2 (enExample) |
| DK (1) | DK3875085T3 (enExample) |
| ES (1) | ES2991523T3 (enExample) |
| FI (1) | FI3875085T3 (enExample) |
| HU (1) | HUE068117T2 (enExample) |
| IL (2) | IL319280A (enExample) |
| MX (3) | MX2021005144A (enExample) |
| PH (1) | PH12021550988A1 (enExample) |
| PL (1) | PL3875085T3 (enExample) |
| PT (1) | PT3875085T (enExample) |
| SG (1) | SG11202104365QA (enExample) |
| WO (1) | WO2020091036A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019167178A1 (ja) | 2018-02-28 | 2019-09-06 | 田辺三菱製薬株式会社 | ３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬を含む薬剤の製造方法 |
| MX2021005144A (es) | 2018-11-02 | 2021-07-15 | Mitsubishi Tanabe Pharma Corp | Suspension de edaravona para administracion oral. |
| US11826352B2 (en) | 2018-11-02 | 2023-11-28 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
| EP3989968A4 (en) * | 2019-07-18 | 2023-07-12 | BDR Pharmaceuticals International Private Limited | ORAL FORMULATIONS OF EDARAVON AND PROCESSES FOR THEIR PREPARATION |
| US12194025B2 (en) | 2020-11-12 | 2025-01-14 | Mitsubishi Tanabe Pharma Corporation | Pharmaceutical composition for oral administration of edaravone and method of administering same |
| CA3198014A1 (en) | 2020-11-12 | 2022-05-19 | Hidetoshi Shimizu | Pharmaceutical composition for oral administration of edaravone and method of administering same |
| GB202103807D0 (en) | 2021-03-18 | 2021-05-05 | Johnson Matthey Plc | A crystalline salt of edaravone, processes for the preparation and use thereof |
| JPWO2023149539A1 (enExample) | 2022-02-03 | 2023-08-10 | ||
| WO2024005187A1 (ja) | 2022-07-01 | 2024-01-04 | 田辺三菱製薬株式会社 | 組成物、およびエダラボンの応答可能性の評価方法 |
| US12343330B2 (en) | 2023-02-16 | 2025-07-01 | Slayback Pharma Llc | Stable pharmaceutical compositions of edaravone |
| CN118178328A (zh) * | 2024-03-21 | 2024-06-14 | 药云(西安)医药技术有限公司 | 依达拉奉包埋物制备方法与其口服制剂 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (ja) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | 脳機能正常化剤 |
| JPH07121861B2 (ja) | 1986-11-25 | 1995-12-25 | 三菱化学株式会社 | ３−メチル−１−フエニル−２−ピラゾロン−５−オンを含有する安定な注射剤 |
| JPH0531523A (ja) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置 |
| JP3402195B2 (ja) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
| JPH1120463A (ja) | 1997-06-30 | 1999-01-26 | Zexel Corp | 車両用デュアルエアコン |
| WO2002034264A1 (en) | 2000-10-24 | 2002-05-02 | Mitsubishi Pharma Corporation | Remedies for amyotrophic lateral sclerosis (als) |
| JP2004091441A (ja) | 2002-09-04 | 2004-03-25 | Mitsubishi Pharma Corp | ピラゾロン誘導体を含有する経口投与製剤 |
| US20080161378A1 (en) | 2004-02-09 | 2008-07-03 | Hiide Yoshino | Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) or Diseases Caused by Als |
| JP5836004B2 (ja) | 2010-08-12 | 2015-12-24 | 日新化成株式会社 | 可溶化剤 |
| CN102824356A (zh) | 2012-09-25 | 2012-12-19 | 江西中医学院 | 一种黄芩苷纳晶混悬剂、纳晶干粉及其制备方法 |
| WO2014134243A1 (en) | 2013-02-27 | 2014-09-04 | Regents Of The University Of Michigan | Pharmaceutical compounds and use of same in cancer and tauopathies |
| JP6336246B2 (ja) | 2013-03-13 | 2018-06-06 | 大同化成工業株式会社 | ナノ粒子化製剤及びその製造方法 |
| CN105878171A (zh) * | 2014-12-22 | 2016-08-24 | 南京海恒医药科技有限公司 | 一种依达拉奉新制剂及其制备方法 |
| EP3247334A1 (en) | 2015-01-20 | 2017-11-29 | Merck Patent GmbH | Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer |
| JP7026609B2 (ja) * | 2016-03-10 | 2022-02-28 | 大日本住友製薬株式会社 | 微細粒子含有組成物およびその製法 |
| CN113768879A (zh) * | 2016-03-16 | 2021-12-10 | 苏州澳宗生物科技有限公司 | 依达拉奉剂型 |
| PL3551181T3 (pl) | 2017-01-17 | 2021-05-31 | Treeway Tw001 B.V. | Leczenie obejmujące doustne lub dożołądkowe podawanie edarawonu |
| AU2017394478B2 (en) * | 2017-01-17 | 2023-07-20 | Treeway Tw001 B.V. | Medical treatment comprising enteral administration of edaravone |
| CA3069048A1 (en) * | 2017-07-06 | 2019-01-10 | Treeway Tw001 B.V. | Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders |
| MX2021005144A (es) * | 2018-11-02 | 2021-07-15 | Mitsubishi Tanabe Pharma Corp | Suspension de edaravona para administracion oral. |
| EP3989968A4 (en) * | 2019-07-18 | 2023-07-12 | BDR Pharmaceuticals International Private Limited | ORAL FORMULATIONS OF EDARAVON AND PROCESSES FOR THEIR PREPARATION |
-
2019
- 2019-11-01 MX MX2021005144A patent/MX2021005144A/es unknown
- 2019-11-01 BR BR112021008197-6A patent/BR112021008197A2/pt unknown
- 2019-11-01 PT PT198807703T patent/PT3875085T/pt unknown
- 2019-11-01 CN CN202311552337.9A patent/CN117398346A/zh active Pending
- 2019-11-01 DK DK19880770.3T patent/DK3875085T3/da active
- 2019-11-01 AR ARP190103206A patent/AR116967A1/es unknown
- 2019-11-01 EP EP19880770.3A patent/EP3875085B1/en active Active
- 2019-11-01 CN CN201980072370.7A patent/CN112969459B/zh active Active
- 2019-11-01 WO PCT/JP2019/043013 patent/WO2020091036A1/ja not_active Ceased
- 2019-11-01 EP EP24181935.8A patent/EP4420724A3/en active Pending
- 2019-11-01 ES ES19880770T patent/ES2991523T3/es active Active
- 2019-11-01 PL PL19880770.3T patent/PL3875085T3/pl unknown
- 2019-11-01 JP JP2020554977A patent/JP7274502B2/ja active Active
- 2019-11-01 CN CN202311552338.3A patent/CN117379369A/zh active Pending
- 2019-11-01 IL IL319280A patent/IL319280A/en unknown
- 2019-11-01 FI FIEP19880770.3T patent/FI3875085T3/fi active
- 2019-11-01 AU AU2019369843A patent/AU2019369843A1/en not_active Abandoned
- 2019-11-01 IL IL282773A patent/IL282773B2/en unknown
- 2019-11-01 HU HUE19880770A patent/HUE068117T2/hu unknown
- 2019-11-01 SG SG11202104365QA patent/SG11202104365QA/en unknown
- 2019-11-01 KR KR1020217016462A patent/KR20210087490A/ko active Pending
- 2019-11-01 CN CN202311552339.8A patent/CN117379370A/zh active Pending
-
2020
- 2020-05-12 US US16/872,741 patent/US10987341B2/en active Active
-
2021
- 2021-03-26 US US17/213,501 patent/US11241416B2/en active Active
- 2021-04-30 MX MX2023009973A patent/MX2023009973A/es unknown
- 2021-04-30 PH PH12021550988A patent/PH12021550988A1/en unknown
- 2021-04-30 MX MX2024000663A patent/MX2024000663A/es unknown
- 2021-12-23 US US17/560,493 patent/US11478450B2/en active Active
-
2022
- 2022-09-22 US US17/934,234 patent/US11957660B2/en active Active
-
2023
- 2023-05-01 JP JP2023075654A patent/JP7828317B2/ja active Active
-
2024
- 2024-03-26 US US18/616,227 patent/US12599586B2/en active Active
-
2025
- 2025-07-21 AU AU2025205635A patent/AU2025205635A1/en active Pending
- 2025-10-06 JP JP2025168147A patent/JP2026010001A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7828317B2 (ja) | 経口投与用エダラボン懸濁剤 | |
| JP6092629B2 (ja) | リファキシミン使用準備済懸濁液 | |
| EA019881B1 (ru) | Стабилизированная суспензия каризбамата для применения в педиатрии | |
| US20250235430A1 (en) | Edaravone suspension for oral administration | |
| US9949990B2 (en) | Oral composition of celecoxib for treatment of pain | |
| TWI924629B (zh) | 經口投予用依達拉奉(Edaravone)懸浮劑 | |
| ES2338972B1 (es) | Composicion farmaceutica liquida de ibuprofeno y codeina para su administracion por via oral, su procedimiento de preparacion y utilizacionde la misma. | |
| RU2810789C2 (ru) | Суспензия эдаравона для перорального введения | |
| BR122024020124A2 (pt) | Suspensão de edaravone para administração oral, kit para a preparação da mesma, agente terapêutico para a ela, e seus usos | |
| HK40113279A (en) | Edaravone suspension for oral administration | |
| HK40053006B (zh) | 用於口服给药的依达拉奉混悬剂 | |
| HK40053006A (en) | Edaravone suspension for oral administration | |
| WO2011107617A1 (es) | Composición farmacéutica líquida de ibuprofeno y codeína para su administración por vía oral, su procedimiento de preparación y utilización de la misma |